Patent Due Diligence Before VC Investment in an Indian Technology Company

A venture investor funding an Indian technology company may be buying into a patent story: a protected product architecture, a device platform, a manufacturing process, or a defensible deeptech roadmap. The diligence question is not simply whether the company has filed applications. It is whether the company owns the relevant inventions, whether the filings support the investment thesis, and whether third-party rights or contractual gaps could erode value after closing.

Why This Matters

A patent schedule can look impressive while concealing fundamental risk. An application may not cover the feature that drives revenue. A founder may have filed personally and never assigned rights to the company. Product development may depend on a university, former employer, consultant or joint-development partner. A granted patent may sit beside unresolved infringement exposure or a licence that limits use, assignment or enforcement.

For investors, this changes valuation and deal structure. Weak ownership can require pre-closing assignments. An uncertain portfolio may support milestone-based funding, specific warranties, disclosure requirements or a post-closing filing programme. Where patents are central to defensibility, diligence should inform the investment decision, not merely complete a closing checklist.

The statutory starting point is the Patents Act, 1970, which addresses persons entitled to apply, specifications, examination, opposition, grant, the register of patents, assignments and infringement-related issues. Patent counsel should apply those provisions to the actual technology and the company's record.

What Counsel Should Review

First, map patents to the product and investment thesis. Request a schedule of Indian and international applications and grants, including application numbers, inventors, applicants, priority dates, prosecution status, jurisdictions and expected commercial use. The team should identify which claims are intended to protect current products, future roadmap features, licensing revenue or defensive positions.

Second, test chain of title. Review incorporation-stage IP transfers, founder assignments, employment invention provisions, consultant agreements, university or incubator arrangements, joint-development agreements and any licences in or out. Confirm whether assignments requiring recordal have been addressed and whether any charge, security interest, exclusive licence or settlement constrains the company's freedom to deal with the asset.

Third, examine portfolio quality at the level proportionate to the investment. That may include claim scope, examination reports, cited prior art, oppositions, renewal status, divisional strategy and whether provisional filings were followed through appropriately. An early-stage investor may prioritise ownership and filing strategy; a later-stage or strategic investor may need a deeper validity, enforceability and freedom-to-operate review.

Fourth, connect findings to transaction documents. Patent-related representations should be matched to the reviewed schedule and disclosed exceptions. High-risk gaps may require execution of assignments, releases, filing actions or licence consents before funds are released. The board should also receive a practical post-closing plan for prosecution budgets, international filing decisions and governance of new inventions.

See also KAS & Co.'s broader services and developing Insights library for technology transaction risk issues.

Typical Timeline and Cost Range

A focused ownership and filing-status review of a small early-stage portfolio can often be scoped within 1 to 2 weeks once complete documents are available. A review involving multiple jurisdictions, material prosecution history, licensing arrangements, or freedom-to-operate analysis commonly requires a longer workstream and coordination with patent agents or technical specialists.

Cost should be scoped by the number of patent families, jurisdictions, agreements and technical questions to be assessed. Investors should ask for a staged scope: red-flag review first, followed by claim-level or product-clearance analysis only where the investment thesis warrants it.

Common Mistakes

1. Counting filings instead of testing relevance. The number of applications says little unless material claims are connected to the product, roadmap and revenue thesis.
2. Assuming the company owns founder or contractor inventions. Ownership needs written support and, where required, completed assignment and recordal steps.
3. Leaving patent findings outside the deal documents. A material gap should translate into a condition, disclosure, warranty, indemnity or agreed remediation plan.

How KAS & Co. Can Help

KAS & Co. assists investors and India-linked technology companies with patent-focused transaction diligence, IP ownership reviews and deal protections that reflect the commercial importance of the technology. For a targeted diligence scope, contact KAS & Co..

FAQs

1. Is a granted Indian patent enough to establish investment-grade IP?

No. A grant is important, but investors still need to assess ownership, remaining term, claim relevance, licences, encumbrances, disputes and whether the protected subject matter supports the company's business model.

2. Should a VC investor commission a freedom-to-operate review?

It depends on product launch risk and investment size. For a business commercialising a core hardware, biotech or deeptech product, infringement exposure may warrant focused clearance work. A very early investment may begin with a red-flag assessment.

3. What if a founder owns a patent personally?

Counsel should determine whether the investment requires assignment or an adequate licence to the company, and complete the necessary documentation before or as a condition to closing.

4. Should international patent filings be reviewed in an India investment?

Yes, where overseas markets, manufacturing or exit buyers matter to value. International filing strategy can be central to expansion readiness and an eventual acquisition outcome.

Sources

• The Patents Act, 1970 - India Code